ProCE Banner Activity

LEAP-015: Phase III Safety Run-in Data With Pembrolizumab + Lenvatinib + Chemotherapy for Advanced Gastroesophageal Cancer

Conference Coverage

Pembrolizumab plus lenvatinib and chemotherapy showed a manageable safety profile and preliminary antitumor activity in patients with advanced gastroesophageal cancers.

Released: January 25, 2023

Expiration: January 24, 2024

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Bristol Myers Squibb

Incyte Corporation

Merck Sharp & Dohme Corp.

Seagen Inc.